Auxilium Pharmaceuticals Inc

Auxilium Pharmaceuticals — Morgan Stanley Healthcare Conference 2014

36 slides from Auxilium Pharmaceuticals's conference presentation, Sep 10, 2014

  1. Slide 1: Morgan Stanley Healthcare Conference Corporate Overview

    Slide 1: Morgan Stanley Healthcare Conference Corporate Overview

    Morgan Stanley Healthcare Conference Corporate Overview September 10, 2014

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor We will make various remarks during this presentation that constitute "forward-looking statements" for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding: the Company's expected financial performance, includin

  3. Slide 3: No Offer or Solicitation

    Slide 3: No Offer or Solicitation

    No Offer or Solicitation No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or

  4. Slide 4: Corporate Overview - Agenda

    Slide 4: Corporate Overview - Agenda

    Corporate Overview - Agenda Corporate Strategy and Business Platform Cost Restructuring Product Portfolio: Growth Opportunities XIAFLEX (Peyronie’s Disease and Dupuytren’s Contracture) STENDRA edex TESTOPEL R&D Pipeline and Franchise Development Label Expansion Opportunities Cellulite Frozen Shoulde

  5. Slide 5: Auxilium Executing Multi-Phase Growth Strategy

    Slide 5: Auxilium Executing Multi-Phase Growth Strategy

    Auxilium Executing Multi-Phase Growth Strategy Acquisition of Actient, STENDRA in-licensing Expanded product portfolio and established anchor leadership position in men’s healthcare Grew from 2 to 12 products PHASE ONE: 2013 PHASE THREE: 2015 & Beyond Fully leverage and grow the base business Divers

  6. Slide 6: Auxilium: Cost Restructuring Increases Efficiency

    Slide 6: Auxilium: Cost Restructuring Increases Efficiency

    Auxilium: Cost Restructuring Increases Efficiency Corporate restructuring designed to streamline operations, maximize cash flow and drive sustainable earnings growth Focus on leaner operating model and continued importance of effective execution: Expected to reduce annual operating expenses by at le

  7. Slide 7: Auxilium Int'l Corp.: Platform for Growth

    Slide 7: Auxilium Int'l Corp.: Platform for Growth

    Auxilium Int’l Corp.: Platform for Growth Merger with QLT designed to create platform to accelerate Auxilium’s transformation Canadian-domiciled structure creates competitive advantage Anticipated effective tax rate of mid 20% range by 2018 Potential for accelerated reduction through M&A and partner

  8. Slide 8: Auxilium Int'l Corp.: Advantaged Platform

    Slide 8: Auxilium Int'l Corp.: Advantaged Platform

    Auxilium Int’l Corp.: Advantaged Platform Value enhancement from the Canadian domicile to existing business Designed to reduce the long-term effective tax rate (ETR) from the high 30% range to the mid 20% range Potential for accelerated reduction in ETR through continued partnering and M&A September

  9. Slide 9: Product Portfolio

    Slide 9: Product Portfolio

    Product Portfolio

  10. Slide 10: Diversified Product Portfolio and R&D Pipeline

    Slide 10: Diversified Product Portfolio and R&D Pipeline

    Diversified Product Portfolio and R&D Pipeline Erectile Dysfunction Low Testosterone Peyronie’s Disease Adhesive Capsulitis Cellulite Orthopedics/ Dermatology PIPELINE TREATMENTS MEN’S HEALTHCARE Additional medications include: Ophthalmology* Impaired Dark Adaptation** PIPELINE TREATMENTS Leber Cong

  11. Slide 11: XIAFLEX: Overall Product Performance

    Slide 11: XIAFLEX: Overall Product Performance

    XIAFLEX: Overall Product Performance Strong initial launch momentum in Peyronie’s disease Stable growth traction in Dupuytren’s contracture 2Q 2014: $26.3M XIAFLEX U.S. Revenues by Quarter +75%

  12. Slide 12: XIAFLEX for PD: Focused Launch Strategy

    Slide 12: XIAFLEX for PD: Focused Launch Strategy

    XIAFLEX for PD: Focused Launch Strategy Category Invasive Surgical1 Invasive Non-Surgical1 Non-Invasive No Treatment2 Description / Examples Plication, grafting, prosthesis Verapamil injection Vitamin E, potaba, colchicine Patient Counts 1,500 – 2,000 3,500 – 4,500 ~52,000 ~38,000 Urology Centers ~1

  13. Slide 13: XIAFLEX for PD: Strong Initial Launch Momentum

    Slide 13: XIAFLEX for PD: Strong Initial Launch Momentum

    XIAFLEX for PD: Strong Initial Launch Momentum Auxilium Advantage; All numbers as of August 18 2014 94% Approved 52% Decision Made 48% Currently in Process PD Patients Submitted Through August 18, 2014 4,332 Total Physicians Certified Through August 18, 2014 1,335

  14. Slide 14: XIAFLEX for PD: Strong Initial Launch Momentum

    Slide 14: XIAFLEX for PD: Strong Initial Launch Momentum

    XIAFLEX for PD: Strong Initial Launch Momentum 6,198 Vials Total * Vials shipped to physicians represents in-market demand. Revenues for PD are recognized by Company when sold to wholesalers. Estimates do not include vials shipped to large hospital centers that treat both PD and DC. Historical adjus

  15. Slide 15: XIAFLEX in DC: Stable Growth Traction

    Slide 15: XIAFLEX in DC: Stable Growth Traction

    XIAFLEX in DC: Stable Growth Traction 7% increase in vial sales over 2Q 2013 Stable XIAFLEX market share 33% YTD through June Increasing awareness & demand for DC procedures Rolling 12-month total procedures: April 2014: 66,324 April 2013: 63,201 4.9 % increase 2011 2012 2013 2014 XIAFLEX in DC: Qua

  16. Slide 16: STENDRA: First ED Drug Approved in Years

    Slide 16: STENDRA: First ED Drug Approved in Years

    STENDRA: First ED Drug Approved in 10 Years Exciting and distinct product profile Rapid – can be taken 30 minutes before sexual activity Able to be taken with food and modest alcohol Designed to be a selective PDE5 inhibitor; low incidence of AEs in clinical trials

  17. Slide 17: STENDRA: Growth in Rx's and Productivity

    Slide 17: STENDRA: Growth in Rx's and Productivity

    STENDRA: Growth in Rx’s and Productivity STENDRA Rx Since Launch IMS Health, 2014; based on all data available as of June 30, 2014; * Revenues recognized by Company at time product shipped to wholesalers $6.1 Million in 2Q Revenues* Increasing number of total prescribers: End of Q1: 5,704 End of Q2:

  18. Slide 18: STENDRA: Initial Launch Traction

    Slide 18: STENDRA: Initial Launch Traction

    Weekly STENDRA TRx Share of Oral ED Market STENDRA: Initial Launch Traction IMS Health, 2014; based on all data available as of September 8, 2014 3.6% 1.6% 0.5% Jan Feb Mar Apr May Jun Jul Aug 5.0%

  19. Slide 19: edex: Continued Market Leadership

    Slide 19: edex: Continued Market Leadership

    edex: Continued Market Leadership Market-leading injectable ED treatment Rapid onset; convenient single-dose dual-chamber cartridge Non-oral ED treatments represent ~0.5% of total ED TRx1 2Q 2014 revenues of $7.5 million 50% increase over 2Q 2013 51.8% retail market share as of 2Q 20141 1 IMS Health

  20. Slide 20: TESTOPEL: Growth Opportunity

    Slide 20: TESTOPEL: Growth Opportunity

    Only FDA-approved long-acting testosterone pellet available Lasts ~3-4 months 1H 2014 net revenues of $36.2 M 15% price increase on April 1 believed to have driven $12-14 million product buy-in in 1Q 2014 A 2Q impact was expected Additional wholesaler destocking believed to have affected 2Q ex-facto

  21. Slide 21: R&D Pipeline and Franchise Management

    Slide 21: R&D Pipeline and Franchise Management

    R&D Pipeline and Franchise Management

  22. Slide 22: Franchise Management: Label Expansion

    Slide 22: Franchise Management: Label Expansion

    Franchise Management: Label Expansion 1 Consumer Impact Research; January 2013 2 Ipsos DC Buying Process, Patient survey Aug-Sept 12, HCP survey Sept-Oct 12, HCP (n= 496, PCP= 126) all specialty samples contain targets and non-targets), DC sufferers n= 177; Brandware 3 Clarity Pharma DC Patient Char

  23. Slide 23: R&D: Cellulite Phase 2a Clinical Trial

    Slide 23: R&D: Cellulite Phase 2a Clinical Trial

    R&D: Cellulite Phase 2a Clinical Trial Phase 2a trial results announced in August 2014 Randomized, placebo-controlled study of 150 women in U.S. Three doses of CCH (low (0.06mg), mid (0.48mg) and high (0.84mg) evaluated Mid and high level CCH doses demonstrated statistically significant improvement

  24. Slide 24: R&D: Cellulite Phase 2a Clinical Trial - Subject B

    Slide 24: R&D: Cellulite Phase 2a Clinical Trial - Subject B

    Subject B – High Dose Texture Photography Day 1 Pre-Treatment Day 73 30 Days Following Last Treatment R&D: Cellulite Phase 2a Clinical Trial

  25. Slide 25: R&D: Cellulite Phase 2a Clinical Trial - Subject C

    Slide 25: R&D: Cellulite Phase 2a Clinical Trial - Subject C

    Subject C – High Dose Texture Photography Day 1 Pre-Treatment Day 73 30 Days Following Last Treatment R&D: Cellulite Phase 2a Clinical Trial

  26. Slide 26: R&D: Frozen Shoulder Syndrome

    Slide 26: R&D: Frozen Shoulder Syndrome

    R&D: Frozen Shoulder Syndrome Prolonged, painful capsular collagen thickening; affects 2-5% of adults Full duration of frozen stage (Stage 2) can last from 1 to 3.5 years Causes pain, stiffness and decreased range of motion ~300,000 cases of FSS are diagnosed annually and ~10% are treated with an in

  27. Slide 27: FSS: Phase 2a Results - Forward Flexion

    Slide 27: FSS: Phase 2a Results - Forward Flexion

    FSS: Phase 2a Results Forward Flexion: Cohort 3 – 0.58 mg / 1 mL 42.9o (41.5%) Overall Improvement 103.4o Baseline 146.3o Post Treatment P<0.05 Comparison to Exercise Cohort

  28. Slide 28: FSS: Phase 2a Results - Shoulder Abduction

    Slide 28: FSS: Phase 2a Results - Shoulder Abduction

    FSS: Phase 2a Results Shoulder Abduction: Cohort 3 – 0.58 mg / 1 mL 81.9o Baseline 135.6o Post Treatment 53.7o (65.6%) Overall Improvement P<0.05 Comparison to Exercise Cohort

  29. Slide 29: Strategic Priorities & Upcoming Milestones

    Slide 29: Strategic Priorities & Upcoming Milestones

    Strategic Priorities & Upcoming Milestones

  30. Slide 30: Strategic Priorities & Milestones Moving Forward

    Slide 30: Strategic Priorities & Milestones Moving Forward

    Strategic Priorities & Milestones Moving Forward Continue to successfully launch two new products: STENDRA for ED and XIAFLEX for PD Grow TESTOPEL and edex use with urologists Drive XIAFLEX to standard of care in Dupuytren’s Maximize value of current portfolio Successfully advance R&D opportunities

  31. Slide 31: fa a] = ® 2. <x

    Slide 31: fa a] = ® 2. <x

    fa a] = ® 2. 2 <x

  32. Slide 32: 2Q 2014 Net Revenue Details

    Slide 32: 2Q 2014 Net Revenue Details

    2Q 2014 Net Revenue Details Increase Increase 2014 2013 (Decrease) 2014 2013 (Decrease) Testim revenues- Net U.S. revenues - brand $11.9 $53.2 -78% $22.8 $98.5 -77% Net U.S. revenues - AG 13.3 - N/A 13.3 - N/A International revenues 0.9 1.2 -25% 1.8 1.4 29% Total Testim revenues $26.1 $54.4 -52% $37

  33. Slide 33: 2Q Reconciliation: GAAP to Non-GAAP Net Loss

    Slide 33: 2Q Reconciliation: GAAP to Non-GAAP Net Loss

    2Q Reconciliation: GAAP to Non-GAAP Net Loss 3 Months Ended June 30, 2014 3 Months Ended June 30, 2013 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 83.0 $ - $ 83.0 $ 100.5 $ - $ 100.5 $ Operating expenses: Cost of goods sold 30.1 (0.1) (a) 30.0 27.2 (4.5) (a) 22.7 Research and d

  34. Slide 34: 2Q Reconciliation: GAAP to Non-GAAP Net Loss

    Slide 34: 2Q Reconciliation: GAAP to Non-GAAP Net Loss

    2Q Reconciliation: GAAP to Non-GAAP Net Loss 3 Months 3 Months Ended June 30, 2014 Ended June 30, 2013 Adjustments to: (a) Costs of goods sold: Employee stock-based compensation (1) (0.1) - Acquired inventory step-up value (2) - (4.5) (0.1) $ (4.5) $ (b) Research and development: Employee stock-base

  35. Slide 35: 1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss

    Slide 35: 1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss

    1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss 6 Months Ended June 30, 2014 6 Months Ended June 30, 2013 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Net revenues* 171.5 $ - $ 171.5 $ 166.7 $ - $ 166.7 $ Operating expenses: Cost of goods sold 48.2 (0.1) (a) 48.1 42.3 (4.6) (a) 37.7 Researc

  36. Slide 36: 1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss

    Slide 36: 1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss

    1H 2014 Reconciliation: GAAP to Non-GAAP Net Loss 6 Months 6 Months Ended June 30, 2014 Ended June 30, 2013 Adjustments to: (a) Costs of goods sold: Employee stock-based compensation (1) (0.1) (0.1) Acquired inventory step-up value (2) - (4.5) (0.1) $ (4.6) $ (b) Research and development: Employee s

Source: SEC EDGAR · 425 filed Sep 10, 2014

More decks from Auxilium Pharmaceuticals Inc